Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gallamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | ACHE | P22303 | 1/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.96 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.96 |
| ▸ | CHRNA7 | P36544 | 16/20 | 0.58 |
| ▸ | CHRNB4 | P30926 | 12/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 9/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.58 |
| ▸ | CHRNA10 | Q9GZZ6 | 2/20 | 0.47 |
| ▸ | CHRNA9 | Q9UGM1 | 2/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gallamine SCHEMBL12638600 | 0.98 | CHRM2 (1.00) | CHRM2ALOX15LMNACHRM1TSHR | |
| SCHEMBL19300483 | 0.93 | CHRM2 (0.90) | CHRM2ALOX15LMNACHRM1TSHR | |
| Gallamine SCHEMBL1736255 | 0.91 | CHRM2 (0.87) | CHRM2ALOX15LMNACHRM1TSHR | |
| SCHEMBL16884476 | 0.86 | CHRM2 (0.77) | CHRM2ALOX15LMNACHRM1TSHR | |
| SCHEMBL8557526 | 0.76 | LMNA (0.62) | CHRM2ALOX15LMNACHRM1TSHR | |
| SCHEMBL3265285 | 0.75 | CHRM2 (0.59) | CHRM2ALOX15LMNACHRM1TSHR | |
| SCHEMBL1238407 | 0.74 | LMNA (0.60) | CHRM2ALOX15LMNACHRM1TSHR | |
| SCHEMBL13658189 | 0.72 | LMNA (0.58) | CHRM2ALOX15LMNACHRM1TSHR | |
| SCHEMBL13385235 | 0.71 | CHRNA7 (1.00) | ALOX15CHRNA7CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL456438 | 0.71 | CHRM2 (0.56) | CHRM2ALOX15LMNACHRM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1494 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| WO-2024211329-A2 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL (US) | 2024-10-10 | — | — | WO | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| EP-4154879-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | Korea Institute of Science and Technology (KR) | 2023-03-29 | — | — | EP | claimed |
| WO-2022250365-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GALAMINE TRIETHIODIDE AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MUSCLE DISEASES | 건국대학교 글로컬산학협력단 | 2022-12-01 | — | — | WO | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| WO-2022023496-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-02-03 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-1328261-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | Minerva Biotechnologies Corporation (US) | 2003-07-23 | — | — | EP | claimed |
| US-20030060487-A1 | Treatment of neurodegenerative disease | MINERVA BIOTECHNOLOGIES CORPORATION | 2003-03-27 | — | — | US | claimed |
| EP-0983060-A4 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2002-04-24 | — | — | EP | claimed |
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX THERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| WO-2001078709-A2 | TREATMENT OF NEURODEGENERATIVE DISEASE | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0983060-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998051282-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-19 | — | — | WO | claimed |
| US-5770222-A | Therapeutic drug delivery systems | IMARX PHARMACEUTICAL CORP. (US) | 1998-06-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060487-A1 | Treatment of neurodegenerative disease | HTT, IAPP, APP | CHRM2 3018/4885ALOX15 3270/4885LMNA 1462/4885 |
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | EXOSC9, EXOSC5, EXOSC4 | CHRM2 556/4885ALOX15 863/4885LMNA 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.